Aeterna begins third pivotal trial of Neovastat

Aeterna (AELA; TSE:AEL) began a pivotal Phase II

Read the full 86 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE